Weight maintenance: Challenges, tools and strategies for primary care physicians

Obesity Reviews

Volumn 17, Issue 1, 2016, Pages 81-93

  Soleymani, T ^a,b   Daniel, S ^a   Garvey, W T ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Maintenance; Obesity; Primary care; Weight loss

Indexed keywords

ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT MAINTENANCE; COMORBIDITY; DIET; GENERAL PRACTITIONER; HUMAN; LIFESTYLE MODIFICATION; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; WEIGHT GAIN; WEIGHT REDUCTION; ANAMNESIS; BEHAVIOR THERAPY; CLINICAL PRACTICE; HEALTH CARE SURVEY; PRIMARY HEALTH CARE; PROCEDURES; STANDARDS; TRENDS;

BEHAVIOR THERAPY; HEALTH CARE SURVEYS; HUMANS; MEDICAL HISTORY TAKING; OBESITY; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; WEIGHT LOSS;

EID: 84958858679     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12322     Document Type: Article

References (133)

1. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract 2012; 18: 642-648.
2. Tsigos C, Hainer V, Basdevant A etal. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1: 106-116.
3. Garvey WT, Garber AJ, Mechanick JI etal. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014; 20: 977-989.
4. World Health Organization. Obesity and overweight. Fact Sheet No. 311. 2014. [WWW document]. URL http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed April 2015).
5. World Health Organization. Obesity. [WWW document]. URL http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity (accessed April 2015).
6. Fruhbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 2013; 6: 117-120.
7. de Onis M, Blossner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010; 92: 1257-1264.
8. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
9. Vincent HK, Heywood K, Connelly J, Hurley RW. Obesity and weight loss in the treatment and prevention of osteoarthritis. PM R 2012; 4: S59-S67.
10. Kuna ST, Reboussin DM, Borradaile KE etal. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep 2013; 36: 641-649.
11. Garber AJ. Obesity and type 2 diabetes: which patients are at risk? Diabetes Obes Metab 2012; 14: 399-408.
12. Jensen MD, Ryan DH, Apovian CM etal. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63: 2985-3023.
13. Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract 2013; 19: 864-874.
14. Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med 2009; 24: 1073-1079.
15. Jensen MD, Ryan DH, Apovian CM etal. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129: S102-S138.
16. Stalonas PM, Perri MG, Kerzner AB. Do behavioral treatments of obesity last? A five-year follow-up investigation. Addict Behav 1984; 9: 175-183.
17. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989; 13(Suppl. 2): 39-46.
18. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001; 21: 323-341.
19. Bray G, Look M, Ryan D. Treatment of the obese patient in primary care: targeting and meeting goals and expectations. Postgrad Med 2013; 125: 67-77.
20. Jarlenski MP, Gudzune KA, Bennett WL, Cooper LA, Bleich SN. Insurance coverage for weight loss: overweight adults' views. Am J Prev Med 2013; 44: 453-458.
21. Waring ME, Roberts MB, Parker DR, Eaton CB. Documentation and management of overweight and obesity in primary care. J Am Board Fam Med 2009; 22: 544-552.
22. Ard J. Obesity in the US: what is the best role for primary care? BMJ 2015; 350: g7846.
23. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014; 95: 53-66.
24. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005; 82: 222S-225.
25. Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes (Lond) 2006; 30: 391-399.
26. Eckel RH, Jakicic JM, Ard JD etal. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2960-2984.
27. Strain GW, Kolotkin RL, Dakin GF etal. The effects of weight loss after bariatric surgery on health-related quality of life and depression. Nutr Diabetes 2014; 4: e132.
28. Emerenziani S, Rescio MP, Guarino MP, Cicala M. Gastro-esophageal reflux disease and obesity, where is the link? World J Gastroenterol 2013; 19: 6536-6539.
29. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012; 30: 496-506.
30. Foster GD, Borradaile KE, Sanders MH etal. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009; 169: 1619-1626.
31. Whitcomb EL, Subak LL. Effect of weight loss on urinary incontinence in women. Open Access J Urol 2011; 3: 123-132.
32. Aucott L, Poobalan A, Smith WCS, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005; 45: 1035-1041.
33. Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension 2009; 54: 756-762.
34. Crawford D, Jeffery RW, French SA. Can anyone successfully control their weight? Findings of a three year community-based study of men and women. Int J Obes Relat Metab Disord 2000; 24: 1107-1110.
35. Field AE, Wing RR, Manson JE, Spiegelman DL, Willett WC. Relationship of a large weight loss to long-term weight change among young and middle-aged US women. Int J Obes Relat Metab Disord 2001; 25: 1113-1121.
36. Klein S. Outcome success in obesity. Obes Res 2001; 9(Suppl. 4): 354S-358.
37. Lowe MR, Miller-Kovach K, Phelan S. Weight-loss maintenance in overweight individuals one to five years following successful completion of a commercial weight loss program. Int J Obes Relat Metab Disord 2001; 25: 325-331.
38. Avenell A, Broom J, Brown TJ etal. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii-iv, 1-182.
39. Kukkonen-Harjula KT, Borg PT, Nenonen AM, Fogelholm MG. Effects of a weight maintenance program with or without exercise on the metabolic syndrome: a randomized trial in obese men. Prev Med 2005; 41: 784-790.
40. Poobalan AS, Aucott LS, Smith WC, Avenell A, Jung R, Broom J. Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev 2007; 8: 503-513.
41. Arterburn DE, Olsen MK, Smith VA etal. Association between bariatric surgery and long-term survival. JAMA 2015; 313: 62-70.
42. Li G, Zhang P, Wang J etal. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2: 474-480.
43. Maclean PS, Bergouignan A, Cornier MA, Jackman MR. Biology's response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol 2011; 301: R581-R600.
44. Knowler WC, Fowler SE, Hamman RF etal. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
45. Purnell JQ, Zinman B, Brunzell JD, Group DER. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation 2013; 127: 180-187.
46. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643-648.
47. Mannucci E, Dicembrini I, Lauria A, Pozzilli P. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care 2013; 36(Suppl. 2): S259-S263.
48. Kroeger CM, Hoddy KK, Varady KA. Impact of weight regain on metabolic disease risk: a review of human trials. J Obes 2014; 2014: 614519.
49. Beavers DP, Beavers KM, Lyles MF, Nicklas BJ. Cardiometabolic risk after weight loss and subsequent weight regain in overweight and obese postmenopausal women. J Gerontol A Biol Sci Med Sci 2013; 68: 691-698.
50. Klein S, Burke LE, Bray GA etal. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-2967.
51. Wadden TA, Anderson DA, Foster GD. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes Res 1999; 7: 170-178.
52. Thomas JG, Bond DS, Phelan S, Hill JO, Wing RR. Weight-loss maintenance for 10 years in the National Weight Control Registry. Am J Prev Med 2014; 46: 17-23.
53. Wyatt HR, Grunwald GK, Mosca CL, Klem ML, Wing RR, Hill JO. Long-term weight loss and breakfast in subjects in the National Weight Control Registry. Obes Res 2002; 10: 78-82.
54. Catenacci VA, Odgen L, Phelan S etal. Dietary habits and weight maintenance success in high versus low exercisers in the national weight Control Registry. J Phys Act Health 2014; 11: 1540-1548.
55. National Weight Control Registry. Facts. [WWW document]. URL http://www.nwcr.ws/Research/default.htm (accessed April 2015).
56. Phelan S, Wyatt HR, Hill JO, Wing RR. Are the eating and exercise habits of successful weight losers changing? Obesity (Silver Spring) 2006; 14: 710-716.
57. Catenacci VA, Pan Z, Thomas JG etal. Low/no calorie sweetened beverage consumption in the National Weight Control Registry. Obesity (Silver Spring) 2014; 22: 2244-2251.
58. Raynor DA, Phelan S, Hill JO, Wing RR. Television viewing and long-term weight maintenance: results from the National Weight Control Registry. Obesity (Silver Spring) 2006; 14: 1816-1824.
59. Pi-Sunyer X, Blackburn G, Brancati FL etal. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-1383.
60. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575.
61. Look Ahead Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014; 22: 5-13.
62. Wadden TA, Neiberg RH, Wing RR etal. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011; 19: 1987-1998.
63. Knowler WC, Barrett-Connor E, Fowler SE etal. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
64. Orchard TJ, Temprosa M, Goldberg R etal. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619.
65. Delahanty LM, Pan Q, Jablonski KA etal. Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the diabetes prevention program. Diabetes Care 2014; 37: 2738-2745.
66. Milsom VA, Middleton KM, Perri MG. Successful long-term weight loss maintenance in a rural population. Clin Interv Aging 2011; 6: 303-309.
67. Sherwood NE, Crain AL, Martinson BC etal. Enhancing long-term weight loss maintenance: 2 year results from the Keep It Off randomized controlled trial. Prev Med 2013; 56: 171-177.
68. Sherwood NE, Crain AL, Martinson BC etal. Keep it off: a phone-based intervention for long-term weight-loss maintenance. Contemp Clin Trials 2011; 32: 551-560.
69. Svetkey LP, Stevens VJ, Brantley PJ etal. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA 2008; 299: 1139-1148.
70. Tyson CC, Appel LJ, Vollmer WM etal. Impact of 5-year weight change on blood pressure: results from the Weight Loss Maintenance trial. J Clin Hypertens (Greenwich) 2013; 15: 458-464.
71. Svetkey LP, Ard JD, Stevens VJ etal. Predictors of long-term weight loss in adults with modest initial weight loss, by sex and race. Obesity (Silver Spring) 2012; 20: 1820-1828.
72. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord 2003; 27: 537-549.
73. Finley CE, Barlow CE, Greenway FL, Rock CL, Rolls BJ, Blair SN. Retention rates and weight loss in a commercial weight loss program. Int J Obes (Lond) 2007; 31: 292-298.
74. Foster GD, Borradaile KE, Vander Veur SS etal. The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. Postgrad Med 2009; 121: 113-118.
75. Wing RR, Hamman RF, Bray GA etal. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res 2004; 12: 1426-1434.
76. Coughlin JW, Gullion CM, Brantley PJ etal. Behavioral mediators of treatment effects in the weight loss maintenance trial. Ann Behav Med 2013; 46: 369-381.
77. Raynor HA, Van Walleghen EL, Bachman JL, Looney SM, Phelan S, Wing RR. Dietary energy density and successful weight loss maintenance. Eat Behav 2011; 12: 119-125.
78. Donnelly JE, Blair SN, Jakicic JM etal. American College of Sports Medicine position stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009; 41: 459-471.
79. Chambers JA, Swanson V. Stories of weight management: factors associated with successful and unsuccessful weight maintenance. Br J Health Psychol 2012; 17: 223-243.
80. Moyer VA. Screening for and management of obesity in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2012; 157: 373-378.
81. Levian C, Ruiz E, Yang X. The pathogenesis of obesity from a genomic and systems biology perspective. Yale J Biol Med 2014; 87: 113-126.
82. MacLean PS, Wing RR, Davidson T etal. NIH working group report: Innovative research to improve maintenance of weight loss. Obesity (Silver Spring) 2015; 23: 7-15.
83. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628.
84. Ebbeling CB, Swain JF, Feldman HA etal. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA 2012; 307: 2627-2634.
85. Sumithran P, Prendergast LA, Delbridge E etal. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
86. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (Lond) 2013; 124: 231-241.
87. Doucet E, Imbeault P, St-Pierre S etal. Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. Int J Obes Relat Metab Disord 2000; 24: 906-914.
88. Ochner CN, Barrios DM, Lee CD, Pi-Sunyer FX. Biological mechanisms that promote weight regain following weight loss in obese humans. Physiol Behav 2013; 120: 106-113.
89. US Food and Drug Administration. Orlistat (marketed as Alli and Xenical) Information. 2013. [WWW document]. URL http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm180076.htm (accessed April 2015).
90. Food and Drug Administration. FDA news release. 2014. FDA approves weight-management drug Saxenda. [WWW document]. URL http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm (accessed July 2015).
91. Novo Nordisk. Saxenda® approved in Europe for the treatment of obesity. 2015. [WWW document]. URL http://www.novonordisk.com/bin/getPDF.1905678.pdf (accessed July 2015).
92. US Food and Drug Administration. Qysmia (phentermine/topiramate ER). [WWW document]. URL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf (accessed July 2015).
93. Arena Pharmaceuticals GmbH. Belviq (lorcaserin) prescribing information. 2012. [WWW document]. URL https://www.belviq.com/pdf/Belviq_Prescribing_information.pdf (accessed July 2015).
94. Takeda Pharmaceuticals USA Inc. Contrave (naltrexone/bupropion ER) prescribing information. 2014. [WWW document]. URL http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=305dd67e-2a45-4f66-a1ca-6a0f3eb17d31 (accessed July 2015).
95. US Food and Drug Administration. Patient Information XENICAL (orlistat) capsules. 2013. [WWW document]. URL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020766s033lbl.pdf. (accessed July 2015).
96. Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf 2013; 12: 741-756.
97. Garvey WT, Ryan DH, Look M etal. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
98. Allison DB, Gadde KM, Garvey WT etal. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-342.
99. Fidler MC, Sanchez M, Raether B etal. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-3077.
100. O'Neil PM, Smith SR, Weissman NJ etal. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20: 1426-1436.
101. Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts 2011; 4: 489-494.
102. Greenway FL, Fujioka K, Plodkowski RA etal. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
103. Wadden TA, Foreyt JP, Foster GD etal. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19: 110-120.
104. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
105. Genentech. Xenical (orlistat) prescribing information. 2013. [WWW document]. URL http://www.gene.com/download/pdf/xenical_prescribing.pdf (accessed July 2015).
106. Hill JO, Hauptman J, Anderson JW etal. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69: 1108-1116.
107. Dombrowski SU, Knittle K, Avenell A, Araujo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014; 348: g2646.
108. Novo Nordisk. Saxenda (liraglutide [rDNA origin] injection). Highlights of prescribing information. 2014. [WWW document]. URL http://novo-pi.nnittest.com/saxenda.pdf (accessed July 2015).
109. Novo Nordisk. Victoza (liraglutide [rDNA origin] injection). Highlights of prescribing information. 2013. [WWW document]. URL http://www.novo-pi.com/victoza.pdf (accessed July 2015).
110. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009; 23: 463-477.
111. Astrup A, Rossner S, Van Gaal L etal. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
112. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
113. Wadden TA, Hollander P, Klein S etal. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37: 1514.
114. Pi-Sunyer X, Astrup A, Fujioka K etal. A randomized, controlled trial of 3.0mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
115. Nauck M, Frid A, Hermansen K etal. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
116. European Medicines Agency. Questions and answers on the review of orlistat-containing medicines. 2012. [WWW document]. URL http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Orlistat_31/WC500122883.pdf (accessed April 2015).
117. Smith SR, Weissman NJ, Anderson CM etal. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
118. Novo Nordisk. Treatment with Saxenda® for three years reduced the risk of developing type 2 diabetes compared with placebo. 2015. [WWW document]. URL http://www.novonordisk.com/bin/getPDF.1923542.pdf (accessed July 2015).
119. ClinicalTrials.gov. Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™ - obesity and pre-diabetes. [WWW document]. URL https://clinicaltrials.gov/ct2/show/NCT01272219?term=scale+and+prediabetes&rank=1 (accessed July 2015).
120. ClinicalTrials.gov. Cardiovascular outcomes study of naltrexone SR/bupropion SR in overweight and obese subjects with cardiovascular risk factors (the Light Study). [WWW document]. URL https://clinicaltrials.gov/ct2/show/NCT01601704?term=Naltrexone%2Fbupropion&rank=14 (accessed December 2014).
121. Sjostrom L, Lindroos AK, Peltonen M etal. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
122. Madura JA, 2nd, Dibaise JK. Quick fix or long-term cure? Pros and cons of bariatric surgery. F1000 Med Rep 2012; 4: 19.
123. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219-234.
124. Garber AJ, Abrahamson MJ, Barzilay JI etal. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract 2013; 19: 536-557.
125. U. S. Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med 2003; 139: 930-932.
126. Kissler HJ, Settmacher U. Bariatric surgery to treat obesity. Semin Nephrol 2013; 33: 75-89.
127. Adams TD, Davidson LE, Litwin SE etal. Health benefits of gastric bypass surgery after 6 years. JAMA 2012; 308: 1122-1131.
128. Cooper TC, Simmons EB, Webb K, Burns JL, Kushner RF. Trends in weight regain following roux-en-Y gastric bypass (RYGB) bariatric surgery. Obes Surg 2015; 25: 1474-1481.
129. Johnson Stoklossa C, Atwal S. Nutrition care for patients with weight regain after bariatric surgery. Gastroenterol Res Pract 2013; 2013: 256145.
130. Kalarchian MA, Marcus MD, Courcoulas AP, Cheng Y, Levine MD, Josbeno D. Optimizing long-term weight control after bariatric surgery: a pilot study. Surg Obes Relat Dis 2012; 8: 710-715.
131. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in primary care practice: a narrative review. Ann N Y Acad Sci 2013; 1281: 191-206.
132. Ko JY, Brown DR, Galuska DA, Zhang J, Blanck HM, Ainsworth BE. Weight loss advice U.S. obese adults receive from health care professionals. Prev Med 2008; 47: 587-592.
133. Madigan CD, Daley AJ, Lewis AL, Jolly K, Aveyard P. Which weight-loss programmes are as effective as Weight Watchers®? Non-inferiority analysis. Br J Gen Pract 2014; 64: e128-e136.